Psoriatic arthritis (literature review)

Psoriatic arthritis (PsA) is a chronic immune-inflammatory progressive disease of the musculoskeletal system observed in psoriasis, which affects the joints, spine and entheses; it occurs in the form of arthritis, dactylitis, enthesitis, and can also manifest as spondylitis or sacroiliitis. The etiology of PsA is unknown, but the pathogenesis has been studied in more detail. Under the influence of external factors, such as infectious agents (viruses, bacteria, fungi), neuropsychic stress, injuries, drugs, changes in intestinal microbiota, etc., genetically predisposed individuals experience activation of the immune system, both congenital and acquired. Currently, there are 5 clinical forms of PsA: predominantly lesion of the distal interphalangeal joints of the hands and feet, distal form; mutilating arthritis; psoriatic spondylitis; asymmetric mono-oligoarthritis; symmetrical polyarthritis, rheumatoid-like form. Along with the characteristic symptomsof skin and joint damage, patients with PsA note a decrease in the quality of life, general malaise, fever, enlarged lymph Review nodes, weight loss, signs of comorbid pathology (obesity, diabetes, cardiovascular diseases). Arthritis is accompanied by tendinitis, synovitis, enthesitis. Isolated spinal damage (psoriatic spondylitis) is rare, it is usually combined with peripheral arthritis, characterized by pain in the spine, dysfunction, curvature. Differential diagnostics are carried out with rheumatoid arthritis, gout, ankylosing spondylitis, polyosteoarthritis, infectious forms of joint damage, joint damage in chronic inflammatory bowel diseases. Treatment of PsA should include medication, physiotherapy and spa treatment. Usually, treatment of PsA begins with the use of such drugs as methotrexate, leflunomide, sulfasalazine, cyclosporine A; non-steroidal anti-inflammatory drugs and intra-articular administration of glucocorticosteroids are used as an auxiliary agent, they are classified as symptom-modifying drugs, they partially improve the patient’s quality of life, reduce pain, but have little effect on the progression of the pathological process. In the absence of an effect from previously conducted treatment and contraindications, genetically engineered biological drugs are used.

1. Znamenskaya L.F., Melekhina L.E., Bogdanova E.V. et al. Psoriasis incidence and prevalence in the Russian Federation. Vestnik dermatologii i venerologii = Bulletin of Dermatology and Venereology 2012;88(5):20-9. (In Russ.). DOI: 10.25208/vdv724

2. Terentyev S.Yu., Ermoshina N.P., Yakovleva N.V. Psychological features of eczematous and psoriatic patients. Rossiyskiy medikobiologicheskiy vestnik im. akad. I.P. Pavlova = Acad. I.P. Pavlov Medical Biological Herald 2009;17(3):1-6. (In Russ.).

3. Korotaeva T.V., Mishina O.S. Psoriaticheskii artrit. Moscow, 2014. (In Russ.).

4. Arthropathic psoriasis. Psoriatic arthritis. Clinical Guidelines, 2024. (In Russ.).

5. Smolnikova M.V., Smirnova S.V., Barilo A.A. Features of immunopathogenesis of psoriasis and psoriatic arthritis. Fundamentalnie issledovaniya = Fundamental Research 2015;(1- 7):1443-7. (In Russ.).

6. Gorbunova D.Yu., Morgunova Z.A., Uryasyev O.M. Clinical and laboratory peculiarities of combined clinical course of metabolic and articular syndromes. Rossiyskiy medikobiologicheskiy vestnik im. akad. I.P. Pavlova = Acad. I.P. Pavlov Medical Biological Herald 2018;26(2):229-37. (In Russ.). DOI: 10.23888/PAVLOVJ2018262229-237

7. Diani M., Altomare G., Reali E. T cell responses in psoriasis and psoriatic arthritis. Autoimmun Rev 2015;14(4):286-92. DOI: 10.1016/j.autrev.2014.11.012.

8. Oliveira-Tore C.F., Moraes A.G., Martinez G.F. et al. Genetic polymorphisms of toll-like receptors 2 and 9 as susceptibility factors for the development of ankylosing spondylitis and psoriatic arthritis. J Immunol Res 2019;2019:1492092. DOI: 10.1155/2019/1492092.

9. Williamson L., Dockerty J.L., Dalbeth N. et al. Clinical assessment of sacroiliitis and HLA-B27 are poor predictors of sacroiliitis diagnosed by magnetic resonance imaging in psoriatic arthritis. Rheumatology (Oxford) 2004;43(1):85-8. DOI: 10.1093/rheumatology/keg47

10. Lopez-Larrea C., Torre Alonso J.C., Rodriguez Perez A., Coto E. HLA antigens in psoriatic arthritis subtypes of a Spanish population. Ann Rheum Dis 1990;49(5):318-9. DOI: 10.1136/ard.49.5.318

11. Liao H.T., Lin K.C., Chang Y.T. et al. Human leukocyte antigen and clinical and demographic characteristics in psoriatic arthritis and psoriasis in Chinese patients. J Rheumatol 2008;35(5):891-5.

12. Winchester R., Minevich G., Steshenko V. et al. HLA associations reveal genetic heterogeneity in psoriatic arthritis and in the psoriasis phenotype. Arthritis Rheum 2012;64(4):1134-44. DOI: 10.1002/art.33415

13. Badokin V.V., Troshkina I.A., Guseva I.A. Psoriatic arthritis: role of genetic component in disease’s clinical manifestation. Doktor.ru 2012;(2):44-9. Available at: https://cyberleninka.ru/article/n/znachenie-geneticheskoy-komponenty-v-klinicheskoyprezentatsii-psoriaticheskogo-artrita (In Russ.).

14. Chandran V., Tolusso D., Cook R., Gladman D. Risk factors for axial inflammatory arthritis in patients with psoriatic arthritis. J Rheumatol 2010;37(4):809-15. DOI: 10.3899/jrheum.091059

15. Haroon M., Winchester R., Giles J.T. et al. Certain class I HLA alleles and haplotypes implicated in susceptibility play a role in determining specific features of the psoriatic arthritis phenotype. Ann Rheum Dis 2016;75(1):155-62. DOI: 10.1136/annrheumdis-2014-205461

16. Polachek A., Cook R., Chandran V. et al. The association between HLA genetic susceptibility markers and sonographic enthesitis in psoriatic arthritis. Arthritis Rheumatol 2018;70(5):756-62. DOI: 10.1002/art.40423

17. Eastmond C.J. Psoriatic arthritis: genetics and HLA antigens. Baillieres Clin Rheumatol 1994;8(2):263-76. DOI: 10.1016/s0950-3579(94)80018-9

18. Gladman D.D., Farewell V.T., Kopciuk K.A., Cook R.J. HLA markers and progression in psoriatic arthritis. J Rheumatol 1998;25(4):730-3.

19. Trabace S., Cappellacci S., Ciccarone P. et al. Psoriatic arthritis: a clinical, radiological and genetic study of 58 Italian patients. Acta Derm Venereol Suppl (Stockh) 1994;186:69-70.

20. Korotaeva T.V. Psoriatic arthritis: pathogenetic justification of current therapeutic approaches. Doctor.Ru 2021;20(7):19-25. (In Russ.). DOI: 10.31550/1727-2378-2021-20-7-19-25

21. Kubanov A.A., Chikin V.V., Karamova A.E. et al. Genetic markers for psoriatic arthritis among patients with psoriasis. Part II: HLA genes. Vestnik dermatologii i venerologii = Bulletin of Dermatology and Venereology 2021;97(5):8-19. (In Russ.). DOI: 10.25208/vdv1269

22. Loffredo S., Ayala F., Marone G.C. et al. Immunopathogenesis of psoriasis and psoriatic arthritis and pharmacological perspectives. Reumatismo 2007;59(Suppl 1):28-39. DOI: 10.4081/reumatismo.2007.1s.28

23. Loffredo S., Ayala F., Marone G. et al. Immunopathogenesis of psoriasis and pharmacological perspectives. J Rheumatol Suppl 2009;83:9-11. DOI: 10.3899/jrheum.090210

24. Smirnova S.V., Smolnikova M.V. Immune pathogenesis of psoriasis and psoriatic arthritis. Meditsinskaya immunologiya = Medical Immunology 2014;16(2):127-38. (In Russ.).

25. Khairutdinov V.R., Belousova I.E., Samtsov A.V. Immune pathogenesis of psoriasis. Vestnik dermatologii i venerologii = Bulletin of Dermatology and Venereology 2016;(4):20-6. (In Russ.).

26. Shilova L.N., Panshina N.N., Chernov A.S. et al. Immunopathologic significance of interleukin-17 in psoriaticarthritis. Sovremennye problemy nauki i obrasovaniya = Modern Review Problems of Science and Education 2015;(6):54. (In Russ.).

27. Ehrenstein M.R., Evans J.G., Singh A. et al. Compromised function of regulatory T cells in rheumatoid arthritis and reversal by anti-TNFalpha therapy. J Exp Med 2004;200:277–85. DOI: 10.1084/jem.20040165

28. Sugiyama H., Gyulai R., Toichi E. et al. Dysfunctional blood and target tissue CD4+CD25high regulatory T cells in psoriasis: mechanism underlying unrestrained pathogenic effector T cell proliferation. J Immunol 2005;174:164-73. DOI: 10.4049/jimmunol.174.1.164

29. Colombo E., Galleri G., Erre G.L. et al. Peripheral blood CD8+ T-cell profiles in patients with psoriatic arthritis: a cross-sectional case-control study. Eur Rev Med Pharmacol Sci 2017;21(22): 5166-71. DOI: 10.26355/eurrev_201711_13834

30. Raychaudhuri S.P., Raychaudhuri S.K., Genovese M.C. IL-17 receptor and its functional significance in psoriatic arthritis. Mol Cell Biochem 2012;359:419-29. DOI: 10.1007/s11010-011-1036-6

31. Leijten E.F., van Kempen T.S., Olde Nordkamp M.A. et al. Tissueresident memory CD8+ T cells from skin differentiate psoriatic arthritis from psoriasis. Arthritis Rheumatol 2021;73(7):1220-32. DOI: 10.1002/art.41652

32. Veale D.J., Ritchlin C., FitzGerald O. Immunopathology of psoriasis and psoriatic arthritis. Ann Rheum Dis 2005;64(Suppl II):ii26-9. DOI: 10.1136/ard.2004.031740

33. Dolcino M., Lunardi C., Ottria A. et al. Crossreactive autoantibodies directed against cutaneous and joint antigens are present in psoriatic arthritis. PLoS One 2014;9(12):e115424. DOI: 10.1371/journal.pone.0115424

34. Ritchlin C. Psoriatic disease - from skin to bone. Nat Clin Pract Rheumatol 2007;3(12):698-706. DOI: 10.1038/ncprheum0670

35. Khismatullina Z.R., Koreshkova K.M. Current concepts of psoriatic arthritis pathogenesis. Klinicheskaya dermatologiya i venerologiya = Clinical Dermatology and Venereology 2022;21(5):583-8. (In Russ.). DOI: 10.17116/klinderma202221051583

36. Fraser A., Fearon U., Billinghurst R.C. et al. Turnover of type II collagen and aggrecan in cartilage matrix at the onset of inflammatory arthritis in humans: relationship to mediators of systemic and local inflammation. Arthritis Rheum 2003;48:3085-95. DOI: 10.1002/art.11331

37. Skougaard M., Ditlev S.B., Stisen Z.R. et al. Four emerging immune cellular blood phenotypes associated with disease duration and activity established in psoriatic arthritis. Arthritis Res Ther 2022;24(1):262. DOI: 10.1186/s13075-022-02956-x

38. Molochkov V.A., Badokin V.A., Albanova V.I., Volnukhin V.A. Psoriasis and psoriatic arthritis. Moscow: KMK. Avtorskaya akademiya, 2007. (In Russ.).

39. Zborovskaya I.A., Kapustina E.A. Psoriatic arthritis. Approaches to diagnosis and treatment. Lekarstvennyy vestnik = Medicinal Bulletin 2016;10(3):10-7. (In Russ.).

40. Zborovskaya I.A., Khanov A.G., Kapustina E.A. Textbook of practical rheumatology: a guide for physicians. Rostov-na-Donu, 2016. (In Russ.).

41. Batkaeva N.V., Donchenko I.Yu., Batkaev E.A. Diagnosis of psoriatic arthritis without disease skin manifestations. RMZh. Meditsinskoe obozrenie = RMJ. Medical Review 2019;3(12):36-8. (In Russ.).

42. Taylor W., Gladman D., Helliwell P. CASPAR Study Group. Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum 2006;54(8):2665-73. DOI: 10.1002/art.21972

43. Smirnova S.V., Smolnikova M.V., Barilo A.A. IL-4, IL-6, IL-10, and TNFα concentrations in the serum of patients with psoriasis and psoriatic arthritis. Citokiny i vospalenie = Cytokines and Inflammation 2015;16(3):31-2. (In Russ.).

44. Ревматология. Под ред. Н.А. Шостак. М.: ГЭОТАР-Медиа, 2012. Rheumatology. Ed.: N.A. Shostak. Moscow: GEOTAR-Media, 2012. (In Russ.).

45. Barilo A.A., Smirnova S.V., Smolnikova M.V. Immunologic parameters of psoriasis patients at different age periods. Rossiyskiy immunologicheskiy zhurnal = Russian Journal of Immunology 2017;11(20):680-1. (In Russ.). DOI: 10.15789/1563-0625-2019-1-69-76

46. Barilo A.A., Smirnova S.V., Smolnikova M.V. The indicators of immunity in patients with psoriatic arthritis depending on the age. Meditsinskaya immunologiya = Medical Immunology 2019;21(1):69-76. (In Russ.).

47. Smagina N.N., Poroshina L.A., Ivashkevich E.A. Differential diagnosis of psoriatic arthritis (literature review). Problemy zdorovya i ekologii = Health and Environmental Issues 2016;(4):19-24. (In Russ.).

48. Uspenskiy Yu.P., Ivanov S.V., Fominikh Yu.A., Gulunov Z.K. Joint syndrome in inflammatory bowel diseases. Eksperimental’naya i klinicheskaya gastroenterologiya = Experimental and Clinical Gastroenterology 2022;198(2):131-8. (In Russ.). DOI: 10.31146/1682-8658-ecg-198-2-131-8

49. Khusainova G.M., Dolgushina A.I., Kuznetcova A.S. Characteristics of the articular syndrome in patients with inflammatory bowel disease. Eksperimental’naya i klinicheskaya gastroenterologiya = Experimental and Clinical Gastroenterology 2020;178(6):95-100. (In Russ.). DOI: 10.31146/1682-8658-ecg-178-6-95-100

50. Korotaeva T.V., Korsakova Yu.L., Loginova E.Yu. et al. Psoriatic arthritis. Clinical guidelines for diagnosis and treatment. Sovremennaya revmatologiya = Modern Rheumatology Journal 2018;12(2):22-35. (In Russ.). DOI: 10/14412/1996-7012-2018-2-22-35.